Jim Cramer says the best is yet to come at Oracle — plus, his thoughts on 4 more stocks

Jim Cramer says the best is yet to come at Oracle — plus, his thoughts on 4 more stocks




Source

Eli Lilly to start late-stage trials on amylin obesity drug after it shows up to 20% weight loss in study 
Health

Eli Lilly to start late-stage trials on amylin obesity drug after it shows up to 20% weight loss in study 

Eli Lilly Biotechnology Center is shown in San Diego, California, March 1, 2023. Mike Blake | Reuters Eli Lilly on Thursday said it will start late-stage trials on its experimental amylin obesity drug next month after it showed encouraging results in a mid-stage study. The highest dose of the weekly injection, called eloralintide, helped patients […]

Read More
Healthy Returns: What to know about Pfizer and Novo Nordisk’s bidding war over obesity biotech Metsera
Health

Healthy Returns: What to know about Pfizer and Novo Nordisk’s bidding war over obesity biotech Metsera

A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Pfizer and Novo Nordisk are in a takeover clash over the obesity biotech Metsera, with both pharmaceutical giants raising their bids for the startup as of Monday.  […]

Read More
Pfizer tops estimates, raises profit guidance even as sales fall
Health

Pfizer tops estimates, raises profit guidance even as sales fall

Smith Collection | Archive Photos | Getty Images Pfizer on Thursday reported third-quarter earnings and revenue that topped estimates and hiked its full-year profit guidance, as cost cuts helped to outweigh declining sales for the period. The pharmaceutical giant now expects its full-year adjusted profit to come in between $3 and $3.15 per share, up […]

Read More